Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older
• People who have been diagnosed with small cell lung cancer (SCLC), confirmed by a tissue or cell sample
• People with either limited-stage SCLC (cancer that has not spread widely, classified as Stage I–III, where the tumour and affected lymph nodes can be safely treated with radiation) or extensive-stage SCLC (cancer that has spread more widely, classified as Stage IV, or where the tumour is too large or spread across too many areas of the lung to be safely treated with full-dose radiation)
• People who have completed standard treatment before joining the trial — for limited-stage SCLC, this means 4–6 cycles of platinum-based chemotherapy combined with either radiation therapy or surgery (with or without additional radiation); for extensive-stage SCLC, this means 4–6 cycles of platinum-based chemotherapy, with or without radiation therapy; immunotherapy given alongside or after standard treatment is also allowed
• People whose cancer scans (CT or MRI of the chest, abdomen, pelvis, and brain) show no signs of the cancer growing or spreading, taken within 28 days before joining the trial
• People whose brain scans show no cancer spread to the brain or the lining of the brain, within 28 days before joining the trial
• People who are being enrolled within 8 weeks of the first day of their last chemotherapy cycle
• People whose general health and ability to carry out daily activities meets a standard rating of 2 or below on a scale used by doctors to measure this (confirm with trial site)
• People whose kidneys are functioning at a sufficient level, as measured by a specific formula (confirm with trial site)
• Women who could become pregnant must have a negative blood pregnancy test within 3 days before joining the trial
• Women who could become pregnant must use a highly effective form of contraception throughout the study and for at least 30 days after the last dose of radiation therapy — accepted methods include combined hormonal contraception, progestogen-only contraception, an intrauterine device (IUD or IUS), bilateral tubal occlusion, a vasectomised partner, or abstinence from sex (assessed in relation to the person's lifestyle and the length of the trial)
• Women who are breastfeeding must stop breastfeeding before the first dose of radiation therapy and for at least 30 days after the last dose
• People who are willing and able to follow the study schedule, including attending appointments and completing follow-up visits
• People who have given written informed consent before being registered or randomly assigned to a treatment group

Who may not be able to join:

• People who have previously had radiation therapy to the brain or whole-brain radiotherapy (note: people who have had a type of targeted brain radiation called stereotactic radiosurgery for non-cancerous conditions may be considered on a case-by-case basis, but this must be discussed with the study coordinators before enrolment)
• People who have a known allergy or reaction to imaging contrast dyes or tracers, or who have insufficient kidney function that prevents the use of contrast agents
• People who cannot have an MRI scan, for example due to having metal implants or other metal objects in the body
• People who have another active blood cancer or solid tumour cancer that is currently being treated
• People who still have unresolved side effects from previous treatment (such as chemotherapy or radiation) that are rated above a certain level of severity at the time of joining the trial (confirm with trial site)
• People who have had unstable chest pain (angina) or heart failure requiring hospitalisation within the 6 months before joining the trial
• People who have had a heart attack within the 6 months before joining the trial
• People who have an active infection requiring treatment at the time of joining the trial
• People who are experiencing a flare-up of chronic obstructive pulmonary disease (COPD) or another acute breathing problem that would prevent them from receiving the study treatment
• People with severe liver disease classified as Child-Pugh class B or C (confirm with trial site)
• People who are HIV positive with a low immune cell count (below 200 CD4 cells per microlitre) — note: people who are HIV positive may still be considered eligible if they are receiving effective HIV treatment and their CD4 count is 200 or above within 16 weeks before joining the trial
• People with any other serious health condition that, in the treating doctor's opinion, could interfere with participation in the study or the ability to receive treatment
• People with a severe neurological condition (including dementia or epilepsy) or psychiatric condition that requires active treatment
• People facing psychological, family, social, or geographical circumstances that could make it difficult to follow the study plan and attend follow-up appointments

Important: Always verify eligibility with the trial site directly before applying.